EnteroMedics Inc (NASDAQ:ETRM) announced the receipt of a European Patent Certificate. The Company was granted Patent number 2254659 titled “Treatment of excess weight …
vBloc Now Program Features Competitive Pricing when Compared to Other Weight Loss Procedures
Investors weren’t impressed with EnteroMedics Inc (NASDAQ:ETRM) latest earnings report, sending shares tumbling nearly 30% in pre-market trading Tuesday. For the three months …
EnteroMedics Inc (NASDAQ:ETRM) announced that its vBloc®Neurometabolic Therapy for the treatment of obesity will be featured on the March 14 episode of the …
EnteroMedics Inc (NASDAQ:ETRM) announced the publication of three-year data from the Company’s VBLOC DM2 Study of vBloc® Neurometabolic Therapy in obese patients with …
EnteroMedics Inc (NASDAQ:ETRM) announced the closing of an underwritten public offering of units for gross proceeds of $19.0 million, which includes the full …
EnteroMedics Inc (NASDAQ:ETRM) investors woke up on Wednesday to find the stock trading 33% lower, after the company announced the pricing of an underwritten public …
In the biotech sector, investors have plenty of reason to cheer EnteroMedics Inc (NASDAQ:ETRM) and GenVec Inc (NASDAQ:GNVC) today as shares continue their …
Shares of EnteroMedics Inc (NASDAQ:ETRM) are on the run today, after the company announced an assessment of real-world, clinical practice weight loss data in …
EnteroMedics Inc (NASDAQ:ETRM) announced the appointment of President and Chief Executive Officer Dan Gladney as Chairman of the Board of Directors, effective October …